In responding to the Therapeutic Goods Administration’s (TGA) interim decision in relation to cannabidiol (CBD) to down-schedule CBD medicines to S3, or pharmacist-only, medicines at appropriate dosage levels, Medicinal Cannabis Industry Australia (MCIA) has recommended further change to the proposed scheduling to ensure that there is an effective pathway for S3 CBD products.
Medicinal cannabis has an important role to play in improving health outcomes. MCIA supports down- scheduling of CBD to S3, which has the potential to provide patients with improved access to a safe low dose cannabis product for medical use.
Medicinal Cannabis Industry Australia has welcomed the interim decision in relation to cannabidiol (CBD) to down-schedule CBD medicines to S3, or pharmacist-only, medicines.
In the interim decision released today, the Therapeutic Goods Administration (TGA) has supported the down scheduling of CBD to allow greater patient access through enabling registered low-dose CBD products to be available as a Schedule 3 medicine.
Medicinal Cannabis Industry Australia (MCIA) is delighted to welcome the establishment of a Parliamentary Friends of Medicinal Cannabis Group in the Federal Parliament.
The group will provide a non-partisan forum for Members and Senators to meet with representatives of the Australian medicinal cannabis industry, medical experts and patient advocates to raise awareness of the applications of medicinal cannabis to Parliamentarians and within the broader community.
MCIA and MCC are pleased to announce that they have entered a collaboration arrangement to create a unified voice for the Australian medicinal cannabis industry.
The Australian medicinal cannabis industry has an important role to play in improving health outcomes for Australian patients. Australia is well placed to lead the world with quality medicinal cannabis, deliver next generation patient well-being, and develop a new export industry.
Medicinal Cannabis Industry Australia (MCIA) has undertaken consultation with the Federal and State Governments and has received confirmation that medicinal cannabis qualifies as an essential service under the public health orders issued by the States and Territories. The public health orders note that sectors/activities where working remotely is not an option, and getting medical care or supplies, are essential services exempt from the social distancing restrictions. Thus, companies will be working to keep the medicinal supply operational and will implement appropriate protocols and practices to ensure the safety of employees and minimise disruptions to supply of products to patients.
“ACannabis is the platform to gain a deep understanding of ground-breaking research, an inside perspective on global trends and a unique opportunity for the agritech and medtech sector to have the conversations required to leverage our advantages” Peter Crock, Chair Medicinal Cannabis Industry Australia
Medicinal Cannabis Industry Australia (MCIA) welcomed the report from The Senate Community Affairs References Committee into Current barriers to patient access to medicinal cannabis in Australia as a key step in assisting patients who are seeking easier and more affordable access to what is a prescription medicine.
in 2019, Medicinal Cannabis Industry Australia (MCIA)
is the peak industry organisation for Australia’s licensed
medicinal cannabis industry, with a focus
on building an industry that enhances wellbeing through facilitating
access to quality Australian medicinal cannabis products for
Australian and global patients.
The Medicinal Cannabis Industry Australia, (MCIA) is launching the inaugural
ACannabis Conference to help define and shape the future of the Australian
Medicinal Cannabis industry.
The event will draw together all facet of the industries ecosystem to connect,
engage and build a framework to support patients’ well-being, enable best practice,
and strengthen growth for the industry.
Medicinal Cannabis Industry Australia (MCIA) is pleased that Minister
Hunt has committed to acting on all 26 recommendations in the
McMillan Report on the review of the Narcotic
Drugs Act 1967, but
seeks further engagement with the Government in relation to the
implementation of the report’s recommendations to ensure that the
intended outcomes are delivered.